Desferal in COVID-19

Phase 2

Recruiting

• Conditions: COVID-19, virus identified.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200506047323N4
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age >18 years
Positive polymerase chain reaction (PCR) test for COVID-19
Primary clinical symptoms
Hospitalized and moderate patients
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm

Exclusion Criteria

Underlying diseases, including renal failure (serum creatinine >2), myocarditis and arrhythmia, anemia (hemoglobin<4-8), lower respiratory tract infection, and asthma
Patients requiring intubation or frequent use of respiratory drugs
Severe and critical patients
History of allergy to studied drug
Pregnancy and breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Viral load. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: Polymerase chain reaction (PCR) test.;Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.

Secondary Outcome Measures

Name	Time	Method
Duration of hospitalization. Timepoint: Time period from admission to discharge. Method of measurement: Patient's file.;C-reactive protein. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: C-RP kit.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.